Person:
KIZILTAN, HURİYE ŞENAY

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HURİYE ŞENAY
Last Name
KIZILTAN
Name
Email Address
Birth Date

Filters

Browse subject tree
2014 - 20183
Reset filters

Settings

Author: MAYADAĞLI, ALPASLAN × Has files: true ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study
    (2014-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞTEKİN, Didem; Coban, GANİME; Eris, ALİ HİKMET; Aydin, TEOMAN; MAYADAGLI, Alparslan; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ÇOBAN, GANİME; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; MAYADAĞLI, ALPASLAN
    Background: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.
  • Thumbnail Image
    PublicationOpen Access
    Effects of Low-Dose Radiation on the Survival of Lung Cancer Patients
    (2018-04-01) Kiziltan, HURİYE ŞENAY; Mayadagli, ALPASLAN; Eris, ALİ HİKMET; Kablan, Ozgur; TURAN, Sezgi; EVREN, Evrim; SUT, Pelin Altinok; Tekce, ERTUĞRUL; BAYIR, Ayse Gunes; KIRSEVER, Esra; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMET; KABLAN, ÖZGÜR; TEKÇE, ERTUĞRUL
    Objective: Some previous studies have shown that low-dose radiotherapy (RT) can increase tumor invasion and metastasis. Multiple RT fields are usually used to prevent the damage to the organs at risk. We performed a clinical study with a concern that low-dose RT might increase invasion or metastasis. Ionizing radiation (IR) can enhance the potential tumor micro-environment by modifying the host micro-metastatic cancer cells.
  • Thumbnail Image
    PublicationOpen Access
    Importance of Performing Radiotherapy and Chemotherapy in the Same Clinic and Bad Prognostic Factors for Small-cell Lung Cancer Patients
    (2016-01-01) KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; TAŞTEKİN, DİDEM; TAŞPINAR, ÖZGÜR; ERİŞ, ALİ HİKMET; ISMAYLOVA, MEDİNA; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMET
    Objective: We evaluated different treatment results reported and showed the effect of treatment at single and multiple clinics for small-cell lung cancer (SCLC). We attempted to show a decreasing impact of chemotherapy (CT) and thoracic radiotherapy (RT) treatment results when implemented at different clinics for SCLC compared to the treatment results at a clinic. Methods: We conducted a retrospective study on 54 non-metastatic SCLC patients who underwent treatments at various clinics. Patients underwent 1–12 courses of CT before they came to the clinic for thoracic RT. RT was performed at 180–400 cGy dose per fraction for a total of 30–52 Gy doses, and patients were followed for 12–60 months. Results: When the study was reviewed, the results showed that the median disease-free survival and survival rates were 8 and 9 months and that the 2-, 5-, and 5-year survival rates were 8%, 6.3%, and 1.8%, respectively. The median progression-free survival rates for 2 and 3 years were 4%, and for 5 years, it was 1.8%. Weight loss for disease-free survival (p=0.01) and superior vena cava syndrome for overall survival (p=0.02) were considered as bad prognostic factors. In this study, acceptable toxicity values were found when the results were compared with those from other studies. Conclusion: We obtained worse results than those from literature data on our SCLC patients who came to our clinic after the progression of their disease. The main causes were identified as insufficient staging and different treatment protocols applied at different clinics. Therefore, we argue that CT and thoracic RT for SCLC must be performed at the same clinic and that the same protocols and staging methods must be used.